Skip to content
Review Open access

Diabetic Dyslipidemia Beyond Conventional Lipid Profiles: Molecular Mechanisms, Emerging Biomarkers and Novel Therapeutic Strategies

Oct 2026 · International Journal of Drug Delivery Technology · 0 citations · 21 references

Abstract

Diabetic dyslipidemia is a complex metabolic abnormality characterized by hypertriglyceridemia, reduced high-density lipoprotein cholesterol (HDL-C), qualitative abnormalities of low-density lipoprotein (LDL) particles, and accumulation of triglyceride-rich lipoproteins (TRLs) and their remnants. Although LDL cholesterol (LDL-C) remains a major therapeutic target for cardiovascular risk reduction, conventional lipid profiles may not fully capture the heterogeneous lipoprotein abnormalities associated with diabetes. Insulin resistance promotes adipose-tissue lipolysis, increases free fatty acid delivery to the liver, stimulates hepatic very-low-density lipoprotein (VLDL) production, and alters lipoprotein clearance. These processes promote the formation of small dense LDL (sdLDL), cholesterol-depleted HDL, remnant lipoproteins and other atherogenic particles. Increasing evidence indicates that apolipoprotein B (ApoB), remnant cholesterol, sdLDL, lipoprotein(a) [Lp(a)], non-HDL cholesterol and other advanced lipid parameters may provide complementary information regarding residual cardiovascular risk. Therapeutic approaches have consequently expanded from statin-based LDL-C reduction to combination therapy involving ezetimibe, PCSK9 inhibitors, bempedoic acid and selected triglyceride-lowering interventions. Emerging approaches targeting apolipoprotein C-III (ApoC-III), angiopoietin-like protein 3 (ANGPTL3), and other regulators of triglyceride-rich lipoprotein metabolism may further broaden the therapeutic landscape. This review discusses the molecular basis of diabetic dyslipidemia, limitations of conventional lipid assessment, emerging biomarkers and contemporary and investigational therapeutic strategies, emphasising the need for a more comprehensive lipoprotein-centred approach to residual cardiovascular risk in diabetes.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.